Alcresta Therapeutics Reveals Significant Growth Improvements for Tube-Fed Children Utilizing RELiZORB
Major Breakthrough in Pediatric Nutrition: RELiZORB® and its Benefits
Alcresta Therapeutics, Inc., based in Waltham, Massachusetts, has recently released compelling evidence showcasing the benefits of its innovative enzyme-based product, RELiZORB, particularly for children aged one to five years who depend on tube feeding. This announcement highlights significant growth enhancements for these children, addressing critical nutritional needs.
As many parents know, children requiring tube feeding often suffer from conditions that hinder nutrient absorption, including fat malabsorption. Dr. Michael Yeh, Chief Medical Officer at Alcresta, remarks on the challenges these children face:
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.